Zoe Hsu

Zoe Hsu

Auto-generated profile, based on publicly available information

Zoe Hsu

Provincial Research Data Services, Alberta Health Services Edmonton Alberta Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Journal of the American Heart Association
Verified
Journal Article
Closed access
FMFinlay McAlister
Finlay McAlister
ZHZoe Hsu
Zoe Hsu
YDYuan Dong
Yuan Dong
RTRoss Tsuyuki
Ross Tsuyuki
CWCarl van Walraven
Carl van Walraven
JBJeffrey A. Bakal
Jeffrey A. Bakal
Background: Because the impact of changes in how outpatient care was delivered during the COVID‐19 pandemic is uncertain, we designed this study to examine the frequency and type of outpatient visits between March 1, 2019 to February 29, 2020 (prepandemic) and from March 1, 2020 to February 28, 2021 (pandemic) and specifically compared outcomes after virtual versus in‐person outpatient visits during the pandemic. Methods and Results: Population‐based retrospective cohort study of all 3.8 million adults in Alberta, Canada. We examined all physician visits and 30‐ and 90‐day outcomes, with a focus on those adults with the cardiovascular ambulatory‐care sensitive conditions heart failure, hypertension, and diabetes. Our primary outcome was emergency department visit or hospitalization, evaluated using survival analysis accounting for competing risk of death. Although in‐person outpatient visits decreased by 38.9% in the year after March 1, 2020 (10 142 184 versus 16 592 599 in the prior year), the introduction of virtual visits (7 152 147; 41.4% of total) meant that total outpatient visits increased by 4.1% in the first year of the pandemic for Albertan adults. Outpatient visit frequency (albeit 41.4% virtual, 58.6% in‐person) and prescribing patterns were stable in the first year after pandemic onset for patients with the cardiovascular ambulatory‐care sensitive conditions we examined, but laboratory test frequency declined by 20% (serum creatinine) to 47% (glycosylated hemoglobin). In the first year of the pandemic, virtual outpatient visits were associated with fewer subsequent emergency department visits or hospitalizations (compared with in‐person visits) for patients with heart failure (adjusted hazard ratio [aHR], 0.90 [95% CI, 0.85–0.96] at 30 days and 0.96 [95% CI, 0.92–1.00] at 90 days), hypertension (aHR, 0.88 [95% CI, 0.85–0.91] and 0.93 [95% CI, 0.91–0.95] at 30 and 90 days), or diabetes (aHR, 0.90 [95% CI, 0.87–0.93] and 0.93 [95% CI, 0.91–0.95] at 30 and 90 days). Conclusions: The adoption and rapid uptake of virtual outpatient care during the COVID‐19 pandemic did not negatively impact frequency of follow‐up, prescribing, or short‐term outcomes, and could have potentially positively impacted some of these for adults with heart failure, diabetes, or hypertension in a setting where there was an active reimbursement policy for virtual visits. Given declines in laboratory monitoring and screening activities, further research is needed to evaluate whether long‐term outcomes will differ.

20 April 2026 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MEManar Elsayed
Manar Elsayed
ZHZoe Hsu
Zoe Hsu
FMFinlay McAlister
Finlay McAlister
WLWilliam D. Leslie
William D. Leslie
LLLisa M. Lix
Lisa M. Lix
CYCarrie Ye
Carrie Ye
Objective: Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA. Methods: We conducted a validation study using the Canadian Research Group of Rheumatology in Immuno‐Oncology (CanRIO) database. Rheumatologist‐confirmed ICI‐IA was the reference standard, defined as new onset of at least one swollen joint on examination or synovitis on imaging following ICI exposure, without another cause or pre‐existing IA. We compared ICD‐9 (714.x and 696.0) and ICD‐10 (M05.x, M06.x, and M07.x) IA diagnostic codes against the reference standard. Seven core case definitions of different combinations of ICD codes from the Physician Claims Database (PCD) and the Discharge Abstract Database were tested. Results were stratified by sex. Sensitivity testing with additional criteria was also evaluated. Results: We included 228 patients in the final analysis: 100 with ICI‐IA and 128 without ICI‐IA. Sensitivity of the tested case definitions ranged from 1.0% to 88.0%, whereas specificity ranged from 86.7% to 100.0%. The case definition with at least one PCD IA code achieved the best balance of sensitivity (88.0%, 95% confidence interval [CI] 81.6%–94.4%) and specificity (86.7%, 95% CI 80.8%–92.6%). Case definition performances were similar between sexes. Additional criteria minimally improved specificity but sacrificed sensitivity. Conclusion: ICD code–based case definitions of ICI‐IA can accurately detect ICI‐IA and can be used to support ICI‐IA surveillance and research with administrative health data.